Inventage Lab launches clinical trials for addiction treatment in Australia

The South Korean company's injection drug IVL3004 alleviates alcohol and narcotics dependence

Inventage Lab launches clinical trials for addiction treatment in Australia
Jae-Young Han 1
2023-01-26 10:23:18 jyhan@hankyung.com
Bio & Pharma

South Korea's Inventage Lab, a developer of a drug delivery system platform, on Wednesday said it received approval from the Human Research Ethics Committee of Australia for a Phase 1 clinical trial for IVL3004, a long-acting injectable medicine for treating alcohol and drug addiction.

IVL3004 uses technology to release a certain concentration of drugs into the body for the target period and blocks dependence on alcohol and drugs from just one injection per month, the company said.

Through a Phase 1 clinical trial on 30 patients, the company will evaluate the safety of IVL3004.

Inventage Lab possesses technology in the development of long-lasting injectable medicine and LNP (lipid nanoparticle) platforms used in mRNA and gene therapy. It was listed on the over-the-counter stock market KOSDAQ in November last year.

Write to Jae-Young Han at jyhan@hankyung.com

GC Biopharma confirms safety of flu vaccine in phase 1 trial

GC Biopharma confirms safety of flu vaccine in phase 1 trial

GC Biopharma Hwasun plant South Korea's leading pharmaceutical company GC Biopharma (Green Cross Corp.) said on Thursday that it has confirmed the safety and immunogenicity of the patch-type influenza vaccine MIMIX-Flu, which is under development jointly with Vaxess Technologies of the United S

Medipost completes first dose of Cartistem in phase 3 clinical trials in Japan

Medipost completes first dose of Cartistem in phase 3 clinical trials in Japan

South Korea's stem cell research company Medipost Co. said on Monday that it has completed the administration of Cartistem, a stem cell treatment for osteoarthritis, to the first patient in a phase 3 clinical trial in Japan.Cartistem received approval for a phase 3 clinical trial from Japan's

S.Biomedics gets approval for Parkinson's disease clinical trials

S.Biomedics gets approval for Parkinson's disease clinical trials

South Korea's biomedicine firm S.Biomedics said on Friday that it has won approval from the Ministry of Food and Drug Safety for phase 1 and 2a clinical trials of Parkinson's disease cell therapy (A9-DPC) using human embryonic stem cell-derived midbrain dopaminergic neural precursor cells.The

CJ applies to FDA for trials of immuno-anticancer drug candidate

CJ applies to FDA for trials of immuno-anticancer drug candidate

CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 and 2 clinical trial protocol for CJRB-101, an immuno-anticancer drug candidate, to the US Food and Drug Administration (FDA). CJRB-101 is a

(* comment hide *}